Compared to Estimates, Baker Hughes (BKR) Q4 Earnings: A Look at Key Metrics
For the quarter ended December 2025, Baker Hughes (BKR) reported revenue of $7.39 billion, up 0.3% over the same period last year. EPS came in at $0.78, compared to $0.70 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $7.06 billion, representing a surprise of +4.68%. The company delivered an EPS surprise of +17.21%, with the consensus EPS estimate being $0.67.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Baker Hughes performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:- Orders - Industrial & Energy Technology: $4.02 billion versus $3.34 billion estimated by four analysts on average.
- Orders - Industrial & Energy Technology - Gas Technology Equipment: $1.79 billion versus the three-analyst average estimate of $1.53 billion.
- Orders - Total: $7.89 billion compared to the $6.9 billion average estimate based on three analysts.
- Orders - Industrial & Energy Technology - Total Gas Technology: $2.76 billion versus $2.34 billion estimated by three analysts on average.
- Revenue- Oilfield Services & Equipment- International: $2.63 billion versus the three-analyst average estimate of $2.67 billion. The reported number represents a year-over-year change of -9.3%.
- Revenue- Oilfield Services & Equipment- North America: $943 million versus the three-analyst average estimate of $944.27 million. The reported number represents a year-over-year change of -2.9%.
- Revenue- Oilfield Services & Equipment- International- Europe/CIS/Sub-Saharan Africa: $624 million compared to the $582.87 million average estimate based on two analysts. The reported number represents a change of -15.7% year over year.
- Revenue- Oilfield Services & Equipment- International- Middle East/Asia: $1.39 billion versus $1.47 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -7.1% change.
- Revenue- Oilfield Services & Equipment: $3.57 billion versus $3.61 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -7.7% change.
- Revenue- Industrial & Energy Technology: $3.81 billion compared to the $3.47 billion average estimate based on six analysts. The reported number represents a change of +9.2% year over year.
- Revenue- Gas Technology Services: $881 million versus the five-analyst average estimate of $833.12 million. The reported number represents a year-over-year change of +10.7%.
- Revenue- Climate Technology Solutions: $229 million compared to the $123.24 million average estimate based on five analysts. The reported number represents a change of +12.3% year over year.
View all Key Company Metrics for Baker Hughes here>>>
Shares of Baker Hughes have returned +18.3% over the past month versus the Zacks S&P 500 composite's -1.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SOL Faces Influx of Exchange Deposits and Security Incident, Market Prospects Remain Unclear

Smart investors increase holdings in Japan ETFs as global tensions challenge ongoing reform efforts

General Motors Sees 9.7% Decline in Q1 Sales Due to Tariff Surge and Severe Winter Weather

uniQure Approaches April 13 Court Deadline Amid Stricter FDA Position on Gene Therapy Study

